JP2022509017A5 - - Google Patents

Info

Publication number
JP2022509017A5
JP2022509017A5 JP2021523752A JP2021523752A JP2022509017A5 JP 2022509017 A5 JP2022509017 A5 JP 2022509017A5 JP 2021523752 A JP2021523752 A JP 2021523752A JP 2021523752 A JP2021523752 A JP 2021523752A JP 2022509017 A5 JP2022509017 A5 JP 2022509017A5
Authority
JP
Japan
Prior art keywords
population
cells
cancer
sequence
genetically engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059585 external-priority patent/WO2020095248A1/en
Publication of JP2022509017A publication Critical patent/JP2022509017A/ja
Publication of JP2022509017A5 publication Critical patent/JP2022509017A5/ja
Priority to JP2024076832A priority Critical patent/JP2024097924A/ja
Pending legal-status Critical Current

Links

JP2021523752A 2018-11-07 2019-11-07 抗ｐｔｋ７免疫細胞癌療法 Pending JP2022509017A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076832A JP2024097924A (ja) 2018-11-07 2024-05-09 抗ｐｔｋ７免疫細胞癌療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862756638P 2018-11-07 2018-11-07
US62/756,638 2018-11-07
US201962910586P 2019-10-04 2019-10-04
US62/910,586 2019-10-04
PCT/IB2019/059585 WO2020095248A1 (en) 2018-11-07 2019-11-07 Anti-ptk7 immune cell cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076832A Division JP2024097924A (ja) 2018-11-07 2024-05-09 抗ｐｔｋ７免疫細胞癌療法

Publications (2)

Publication Number Publication Date
JP2022509017A JP2022509017A (ja) 2022-01-20
JP2022509017A5 true JP2022509017A5 (OSRAM) 2022-11-15

Family

ID=68582072

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523752A Pending JP2022509017A (ja) 2018-11-07 2019-11-07 抗ｐｔｋ７免疫細胞癌療法
JP2024076832A Pending JP2024097924A (ja) 2018-11-07 2024-05-09 抗ｐｔｋ７免疫細胞癌療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076832A Pending JP2024097924A (ja) 2018-11-07 2024-05-09 抗ｐｔｋ７免疫細胞癌療法

Country Status (15)

Country Link
US (3) US12146157B2 (OSRAM)
EP (1) EP3877421A1 (OSRAM)
JP (2) JP2022509017A (OSRAM)
KR (1) KR20210092236A (OSRAM)
CN (1) CN112955472A (OSRAM)
AU (1) AU2019374523A1 (OSRAM)
BR (1) BR112021008083A2 (OSRAM)
CA (1) CA3118830A1 (OSRAM)
CO (1) CO2021005471A2 (OSRAM)
IL (1) IL282532A (OSRAM)
MX (1) MX2021005400A (OSRAM)
PH (1) PH12021551047A1 (OSRAM)
SG (1) SG11202104631SA (OSRAM)
WO (1) WO2020095248A1 (OSRAM)
ZA (1) ZA202102745B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
WO2023084399A1 (en) * 2021-11-09 2023-05-19 Crispr Therapeutics Ag Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7
IL315366A (en) * 2022-03-23 2024-11-01 Synaffix Bv Antibody pairs for targeting PTK7-expressing tumors
CA3249466A1 (en) * 2022-05-17 2023-11-23 Arsenal Biosciences, Inc. MODIFIED RECEIVER SYSTEMS TARGETTING PSMA AND CA9
WO2024054030A1 (ko) * 2022-09-06 2024-03-14 연세대학교 산학협력단 항-ptk7 항체 및 이의 용도
EP4648854A1 (en) * 2023-01-10 2025-11-19 Expression Therapeutics, LLC Engineered t cells
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Ｐｓｍａ及びｃａ９を標的とするシステム
JP2026510870A (ja) * 2023-03-22 2026-04-10 アジレント・テクノロジーズ・インク 免疫組織化学的（ｉｈｃ）ｐｔｋ７スコア化プロトコル及び癌処置を補助する方法
CN117085134A (zh) * 2023-07-19 2023-11-21 浙江大学 Ptk7抑制剂在制备预防或治疗肝癌的药物中的用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US12534529B1 (en) 2024-11-19 2026-01-27 Solve Therapeutics, Inc. PTK7-binding proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
BR0108545A (pt) 2000-02-24 2004-06-29 Xcyte Therapies Inc Estimulação e concentração simultâneas das células
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2006321841C1 (en) * 2005-12-08 2013-01-24 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use
NO2510096T3 (OSRAM) 2009-12-10 2015-03-21
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2015179801A1 (en) * 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
TWI805109B (zh) * 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
KR20170075013A (ko) 2014-10-31 2017-06-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
AU2017306557B2 (en) 2016-08-03 2023-08-03 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
BR112020005938A2 (pt) * 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
AR122014A1 (es) * 2020-05-06 2022-08-03 Crispr Therapeutics Ag Receptor de antígenos quimérico enmascarado específico para la proteína tirosina cinasa de tipo 7 (ptk7) y células inmunitarias que expresan el mismo

Similar Documents

Publication Publication Date Title
JP2022513586A5 (OSRAM)
JP2024097924A5 (OSRAM)
JP2021522820A5 (OSRAM)
JP2022512882A5 (OSRAM)
IL278348B1 (en) Methods and compositions for treating cancer
CA2951355C (en) Car-expressing nk-92 cells as cell therapeutic agents
JP2019532625A5 (OSRAM)
JP2020519641A5 (OSRAM)
US10604740B2 (en) Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein
US20250074965A1 (en) Anti-ptk7 immune cell cancer therapy
JP2019531056A5 (OSRAM)
FI3515487T3 (fi) Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja
JP2020510653A5 (ja) Ｃｅａを標的にする多重特異性結合タンパク質
HRP20171653T1 (hr) Vezna sredstva koja služe ciljano protiv b7-h1
JP2019525771A5 (OSRAM)
JP2020503870A5 (OSRAM)
JP2017506067A5 (OSRAM)
JP2018522072A5 (OSRAM)
JP2021511811A5 (OSRAM)
JP2017537620A5 (OSRAM)
JP2013166763A5 (OSRAM)
JP2011157397A5 (OSRAM)
CA3118824A1 (en) Anti-liv1 immune cell cancer therapy
Gacerez et al. Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression
JP2021534784A5 (OSRAM)